包载携有HSV-TK基因腺病毒PLG微球的制备  

Microsphere Preparation of The Recombinant Adeno-Associated Virus as A Vector for Gene Therapy of Liver Cancer

作　　者：刘自明[1] 严律南[1] 李馨筱[1] 

机构地区：[1]四川大学华西医院普外科,成都610041

出　　处：《中国普外基础与临床杂志》2007年第4期399-402,共4页Chinese Journal of Bases and Clinics In General Surgery

基　　金：国家自然科学基金项目(编号:30170925)

摘　　要：目的探讨载病毒生物降解微球作为肝癌基因靶向治疗载体的可行性。方法用挥发溶媒聚合法制载重组病毒聚乳酸乙二醇〔poly(lactic/glycolic),PLG〕微球,观测其包封率、释放规律及释放病毒的活性。结果PLG微球包封率为19.3%,载病毒微球在100h内释放病毒量接近50%,总的释放时间超过200h,释放出来的病毒保持活性。结论用PLG微球包载重组腺病毒,病毒释放出来后具有很高的活性,其作为肝癌的基因治疗载体具有较好的研究前景。Objective To evaluate the suitability of the biodegradable microsphere encapsulation of adenovirus as a targeting vector for gene therapy of hepatocellular carcinoma. Methods Encapsulate the recombinant adenovirus in PLG [poly （lactic/glycolic）] copolymer by the solution evaporation method, the release test and the bioactivity of viruses incorporated in vitro were studied. Results More than 19.3% of adenovirus was encapsulated in PLG microspheres. The release test shows that the adenovirus was released for more than 200 h, 50% were shed within the first 100 h, and their activity was retained. Conclusion Recombinant adenovirus can be formulated in a polymer preparation of PLG with retention of bioactivity. It may be a valuable vector for the gene therapy of liver cancer.

关 键 词：基因治疗 生物降解微球 腺病毒 HSV-TK基因 肝癌 

分 类 号：R735.7[医药卫生—肿瘤]